Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors

被引：50

作者：

O'Meara, Jeff A. ^{[1
]}

Jakalian, Araz ^{[1
]}

LaPlante, Steven ^{[1
]}

Bonneau, Pierre R. ^{[1
]}

Coulombe, Rene ^{[1
]}

Faucher, Anne-Marie ^{[1
]}

Guse, Ingrid ^{[1
]}

Landry, Serge ^{[1
]}

Racine, Jennifer ^{[1
]}

Simoneau, Bruno ^{[1
]}

Thavonekham, Bounkham ^{[1
]}

Yoakim, Christiane ^{[1
]}

机构：

[1] Boehringer Ingelheim Ltd, Res & Dev, Laval, PQ H7S 2G5, Canada

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 12期

关键词：

NNRTI; scaffold hopping; tertiary amide; tertiary carbamate; thio-tetrazole; tetrazole thioacetanilide;

D O I：

10.1016/j.bmcl.2007.03.097

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

High-throughput screening hit 1 was identified as a potent, broad-spectrum, non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 replication. Analysis of the bound conformation of analogs of this inhibitor via molecular modeling and NMR contributed to the design of novel tertiary amide, carbamate, and thiocarbamate based NNRTIs. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：3362 / 3366

页数：5

共 50 条

[21] Halolactones are potent HIV-1 non-nucleoside reverse transcriptase inhibitors
Han, Xin
Wu, Haoming
Dong, Chune
Tien, Po
Xie, Wei
Wu, Shuwen
Zhou, Hai-Bing
RSC ADVANCES, 2015, 5 (13): : 10005 - 10013
[22] Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors
Ellis, David
Kuhen, Kelli L.
Anaclerio, Beth
Wu, Baogen
Wolff, Karen
Yin, Hong
Bursulaya, Badry
Caldwell, Jeremy
Karanewsky, Donald
He, Yun
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (16) : 4246 - 4251
[23] Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs
Li, Ting-Ting
Pannecouque, Christophe
De Clercq, Erik
Zhuang, Chun-Lin
Chen, Fen-Er
MOLECULES, 2020, 25 (07):
[24] HIV-1 non-nucleoside reverse transcriptase inhibitor
Lloyd, AW
DRUG DISCOVERY TODAY, 1998, 3 (08) : 387 - 387
[25] Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors
Thammaporn, Ratsupa
Ishii, Kentaro
Yagi-Utsumi, Maho
Uchiyama, Susumu
Hannongbua, Supa
Kato, Koichi
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (03) : 450 - 454
[26] Docking study of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Zhou, ZG
Madrid, M
Madura, J
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : U465 - U465
[27] Lead Optimization of Diarylpyrimidines as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase
Zeng, Zhao-Sen
Liang, Yong-Hong
Feng, Xiao-Qing
Chen, Fen-Er
Pannecouque, Christophe
Balzarini, Jan
De Clercq, Erik
CHEMMEDCHEM, 2010, 5 (06) : 837 - 840
[28] The synthesis of several tritiated non-nucleoside, HIV-1 reverse transcriptase inhibitors
Hamill, Terence G.
Brenner, Nancy J.
Eng, Wai-Si
Burns, H. Donald
Journal of Labelled Compounds and Radiopharmaceuticals, 1998, 41 (04): : 319 - 327
[29] Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors
Famiglini, Valeria
Coluccia, Antonio
Brancale, Andrea
Pelliccia, Sveva
La Regina, Giuseppe
Silvestri, Romano
FUTURE MEDICINAL CHEMISTRY, 2013, 5 (18) : 2141 - 2156
[30] Docking studies on novel bisphenylbenzimidazoles (BPBIs) as non-nucleoside inhibitors of HIV-1 reverse transcriptase
Yadav, Madhu
Singh, Anuradha
Singh, Ramendra K.
INDIAN JOURNAL OF CHEMISTRY SECTION B-ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, 2017, 56 (07): : 714 - 723

← 1 2 3 4 5 →